In August 2015, Valeant Pharmaceuticals was the most valuable company on the Toronto Stock Exchange. With a market capitalization of $90 billion, the Canadian pharmaceutical company had outperformed every stock in the S&P 500 over the prior five years, generating returns that made it a darling of hedge fund managers, most notably Bill Ackman of Pershing Square Capital Management, who had invested over $4 billion. Valeant’s CEO, J. Michael Pearson, was celebrated as a visionary who had reinvented the pharmaceutical business model — replacing expensive, uncertain drug research with a streamlined strategy of acquiring existing drugs and raising their prices.
By the spring of 2016, the stock had collapsed by over 90%, the company was under investigation by Congress, the SEC, and federal prosecutors, and Pearson had been ousted. The model that Wall Street had worshipped — buying drugs instead of inventing them, then jacking up prices because sick people have no choice but to pay — was revealed as morally bankrupt and financially unsustainable. Valeant didn’t break any new ground in fraud or deception. What it did was expose the dark heart of American pharmaceutical pricing in a way that made the entire industry a political target.
The Anti-Pharma Pharma Company
Michael Pearson was a former McKinsey consultant who became Valeant’s CEO in 2008 with a radical thesis: pharmaceutical research and development was a waste of money. The industry spent billions developing new drugs, most of which failed in clinical trials. The companies that did produce successful drugs often couldn’t recoup their R&D investment before patents expired and generic competition arrived. Pearson’s alternative: acquire companies that owned drugs with captive patient populations and limited competition, then raise prices aggressively.
The strategy was breathtakingly cynical and — for shareholders — initially very profitable. Valeant slashed R&D spending to a fraction of industry norms, using the savings to fund acquisitions and debt repayment. It bought niche pharmaceutical companies with drugs for conditions like Wilson’s disease, where patient populations were small and alternatives were limited. It bought dermatology companies with prescription acne and anti-fungal treatments. And then it raised prices — not by the single-digit percentages typical of the industry, but by 100%, 200%, even 500% overnight.
The company raised the price of Cuprimine, a drug for Wilson’s disease, from $888 to $26,189 per bottle. It raised the price of Syprine, another Wilson’s disease treatment, by 3,150%. It raised heart drugs Isuprel and Nitropress by 525% and 212% respectively on the same day it acquired them. Patients who depended on these medications for survival had no alternatives and no leverage. They paid, or they suffered.
Philidor: The Shadow Pharmacy
In October 2015, investigative reports by the Southern Investigative Reporting Foundation and Citron Research revealed that Valeant had a secret relationship with Philidor Rx Services, a specialty pharmacy that appeared to exist primarily to ensure that Valeant’s high-priced drugs reached patients even when insurance companies tried to block them. Philidor used aggressive tactics to override insurance company rejections, alter prescriptions, and ensure that the most expensive Valeant products were dispensed even when cheaper alternatives were available.
The relationship between Valeant and Philidor had not been disclosed to investors. Valeant had an option to purchase Philidor and had been consolidating Philidor’s revenue into its own financial statements — inflating reported sales. When the relationship was exposed, Valeant’s stock fell 40% in a single week. The company severed ties with Philidor, but the damage to investor confidence was catastrophic.
The Congressional Spotlight
Valeant’s pricing practices made it the poster child for pharmaceutical price gouging. In April 2016, Pearson and Bill Ackman were hauled before the Senate Special Committee on Aging, where they faced withering questioning about Valeant’s price increases. Pearson, visibly diminished by illness (he had been hospitalized for severe pneumonia), acknowledged that the company had made mistakes. Ackman, who had publicly championed Valeant as his best investment idea, faced uncomfortable questions about whether he had encouraged the predatory pricing strategy.
The political fallout extended beyond Valeant. Hillary Clinton made pharmaceutical pricing a centerpiece of her 2016 presidential campaign after tweeting about Valeant’s competitor Turing Pharmaceuticals (led by the infamous Martin Shkreli). The entire pharmaceutical industry saw its stock prices decline as investors feared a regulatory crackdown on drug pricing.
The Collapse
Valeant’s stock peaked at $262 in August 2015. By March 2016, it had fallen below $30. The company was drowning in over $30 billion of debt accumulated through its acquisition binge, and the price increases that had fueled its financial performance were being reversed under political and regulatory pressure. Pearson was ousted in March 2016 and replaced by Joseph Papa, who was brought in to stabilize the company.
In 2018, Valeant changed its name to Bausch Health Companies in an attempt to distance itself from the toxic brand. The company spent years selling assets and paying down debt. Bill Ackman’s Pershing Square ultimately lost approximately $4 billion on its Valeant investment — one of the worst hedge fund losses in history.
In 2024, the SEC charged Pearson and former CFO Howard Schiller with securities fraud related to the undisclosed Philidor relationship and the resulting inflation of Valeant’s financial results. The legal reckoning, like the stock’s decline, was slow but relentless.
The Lessons of Valeant
Valeant’s model was not illegal in the narrow sense — there is no federal law that prevents a pharmaceutical company from raising drug prices. But it was a model that could only work by exploiting the most vulnerable people in society: patients who needed specific medications to survive and had no alternative. The “innovation” Valeant brought to the pharmaceutical industry was the realization that captive patients represent a form of pricing power that can be ruthlessly exploited.
The deeper lesson is about the limits of financial optimization. Pearson’s McKinsey-trained mind saw the pharmaceutical industry as an efficiency problem — trim the waste (R&D), maximize the revenue (price increases), and leverage the balance sheet (debt-funded acquisitions). On a spreadsheet, it was brilliant. In the real world, it was a company that contributed nothing to medical science, exploited sick people, and ultimately destroyed $85 billion in shareholder value when the model proved unsustainable.
Valeant proved that a company can be technically legal and profoundly destructive at the same time — and that the market, eventually, will punish businesses that create value for no one.
Go Deeper
📚 The Fund by Rob Copeland — While focused on Ray Dalio’s Bridgewater, this book explores the hedge fund culture that championed companies like Valeant.
📖 Explore more on our Recommended Reading page.
More From The Ledger
- Theranos — Another healthcare company that put profits before patients
- General Electric — When financial engineering replaces genuine innovation
- Enron — The McKinsey-bred culture of aggressive optimization taken to its extreme
Browse all stories on our Stories page.
🔔 Subscribe to The Ledger on YouTube for new investigations every week.